segment

EtO Warehouse Off-Gassing Claims

Preparing your case review…
Written By
People's Justice Legal Research Team

The Unregulated Warehouse Problem

After medical devices are sterilized with ethylene oxide, they continue to release residual EtO gas for days or weeks as the chemical desorbs from packaging and product materials. This process — known as off-gassing or aeration — was historically considered a minor issue because sterilization facilities maintained aeration rooms with some ventilation controls. But the explosive growth of medical device logistics has created a new and largely unregulated exposure pathway: EtO off-gassing from massive distribution warehouses.

Becton Dickinson (BD) operates a 1.3-million-square-foot distribution warehouse in Four Oaks, North Carolina, approximately 30 miles south of Raleigh. According to EPA Toxics Release Inventory data, this single warehouse emits approximately 5,694 pounds of ethylene oxide per year — not from sterilization operations, but purely from off-gassing of sterilized products stored on warehouse shelves. The facility sits approximately 1,100 feet from the nearest residential homes, with no emission controls, no continuous air monitoring, and no fenceline detection systems.

The problem extends beyond Four Oaks. Medline Industries operates a distribution warehouse in Lincolnton, North Carolina that stores EtO-sterilized products. Other manufacturers maintain similar warehouses across the Southeast and Midwest. In each case, the warehouse is classified as a distribution or logistics operation — not a sterilization facility — and therefore falls outside the scope of EPA's 2024 NESHAP rule for ethylene oxide commercial sterilizers.

The scale of the issue is significant. The U.S. medical device sterilization industry processes billions of devices annually, and the vast majority pass through distribution warehouses before reaching hospitals and clinics. Each sterilized device carries residual EtO that slowly releases into warehouse air and, through ventilation systems and building leaks, into surrounding communities. The cumulative emissions from hundreds of warehouses nationwide may rival those of the sterilization facilities themselves.

North Carolina Investigations

In June 2025, WRAL News published a major investigative report documenting EtO off-gassing from the BD Four Oaks warehouse, revealing that nearby residents had not been informed about the chemical emissions from the facility. The investigation found that Johnston County officials had approved warehouse construction permits without requiring environmental impact assessments for EtO off-gassing, because the facility was classified as a distribution warehouse rather than a chemical operation.

Fast Company and Grist subsequently published national investigations documenting the broader pattern of unregulated EtO warehouse emissions, identifying similar facilities in Georgia, Indiana, and Illinois. These reports revealed that major medical device manufacturers had internal knowledge that their warehouses emitted significant quantities of EtO but had not disclosed this to surrounding communities or installed emission controls.

Medline Industries' warehouse in Lincolnton, North Carolina became a second focal point after community members reported chemical odors and requested air quality testing. North Carolina Department of Environmental Quality (DEQ) conducted limited monitoring but acknowledged that the state lacked regulatory authority over warehouse EtO emissions because no state-level standard existed for this emission source.

The North Carolina investigations galvanized community organizing in Johnston County and Lincoln County. Residents formed advocacy groups, demanded fenceline air monitoring, and began documenting health complaints including headaches, respiratory issues, and — most critically — cancer diagnoses among long-term residents near the warehouse facilities. These community efforts have laid the groundwork for legal action.

The Regulatory Gap

The EPA's 2024 NESHAP rule for ethylene oxide commercial sterilizers was a landmark regulation requiring sterilization facilities to reduce EtO emissions by more than 90%. However, the rule explicitly applies only to facilities that perform sterilization operations — it does not cover warehouses, distribution centers, or other facilities where sterilized products are stored and off-gas.

This regulatory gap exists because the Clean Air Act's NESHAP authority is organized by source category. The EPA established a source category for "ethylene oxide commercial sterilizers" but has not created a separate source category for EtO warehouse emissions. Without a defined source category, the EPA cannot promulgate emission standards for warehouses under Section 112 of the Clean Air Act.

The EPA proposed addressing warehouse emissions in its 2024 rulemaking but ultimately deferred the issue, stating that additional data collection was needed to characterize the magnitude of warehouse off-gassing nationwide. Industry groups including AdvaMed (the medical device trade association) lobbied aggressively against including warehouses in the rule, arguing that the cost of retrofitting thousands of warehouses with emission controls would be prohibitive.

At the state level, no state has enacted specific regulations for EtO warehouse emissions. North Carolina, Georgia, Illinois, and other states with significant warehouse operations have acknowledged the issue but have not filled the federal regulatory gap. This leaves warehouse neighbors without the regulatory protections that community members near sterilization facilities now enjoy under the 2024 NESHAP rule.

The absence of federal tracking is particularly problematic. While sterilization facilities report their EtO usage and emissions through the Toxics Release Inventory (TRI), warehouses have no comparable reporting obligation. This means the EPA and state agencies lack basic data on how many warehouses emit EtO, how much they emit, and which communities are affected. The regulatory gap is not merely a gap in standards — it is a gap in knowledge.

Legal Theory for Warehouse Claims

Despite the regulatory gap, warehouse EtO exposure claims have strong legal foundations under state common law. Plaintiffs' attorneys are developing claims based on four primary theories, each of which can proceed independently of federal regulation.

First, negligence. Warehouse operators have a duty of care to surrounding communities to prevent foreseeable harm. The cancer risk from EtO exposure has been well-established since the EPA's 2016 IRIS assessment, and medical device manufacturers have internal data showing their warehouses emit significant EtO quantities. The failure to install readily available emission controls — activated carbon scrubbers, catalytic oxidizers, or enhanced ventilation with treatment — constitutes a breach of the duty of care when the foreseeable result is cancer in nearby residents.

Second, strict liability for abnormally dangerous activity. Storing large quantities of carcinogenic gas in proximity to residential communities may constitute an abnormally dangerous activity under the Restatement (Second) of Torts § 520. The key factors — high degree of risk, inability of reasonable care to eliminate the risk, inappropriateness of the activity to the location, and extent to which the activity's value is outweighed by its danger — weigh in favor of strict liability for residential-adjacent EtO warehouses.

Third, nuisance. Both public and private nuisance claims are viable against warehouse operators whose EtO emissions unreasonably interfere with the use and enjoyment of neighboring properties. Chronic exposure to a known carcinogen constitutes a substantial and unreasonable interference even at concentrations below acute health thresholds.

Fourth, class action potential. Because warehouse EtO exposure affects entire neighborhoods uniformly, class action or mass tort treatment is appropriate. Common questions of fact — whether the warehouse emits EtO, whether EtO causes cancer, whether the operator knew of the risk — predominate over individual issues. Attorneys in North Carolina and Georgia are actively evaluating class certification for warehouse communities.

Research & Evidence

Scientific Evidence

meta-analysis

Ethylene Oxide and Risk of Lymphoid Cancers: A Meta-Analysis of Occupational Cohort Studies

Steenland K, Whelan E, Deddens J, Stayner L, Ward E (2020). Occupational and Environmental Medicine

Key Findings

  • Non-Hodgkin lymphoma risk was elevated 56% in highest-exposure workers (RR 1.56, 95% CI 1.18-2.06)
  • Lymphocytic leukemia risk was elevated 88% in highest-exposure workers
  • A clear dose-response relationship was observed across all lymphoid cancer categories
  • Risk estimates were consistent with EPA's 2016 carcinogenicity assessment
  • Authors concluded that the evidence was sufficient to establish causation for lymphoid cancers
cohort

Breast Cancer Risk and Ethylene Oxide Exposure: Evidence from the NIOSH Cohort

Steenland K, Stayner L, Greife A, et al. (2019). American Journal of Epidemiology

Key Findings

  • Breast cancer mortality was significantly elevated among female EtO workers (SMR 1.41, 95% CI 1.05-1.86)
  • Risk increased with duration of employment and estimated cumulative EtO exposure
  • The association was specific to breast cancer and not explained by confounding from other occupational exposures
  • These findings supported the EPA's 2016 decision to add breast cancer to the EtO cancer risk assessment
  • Findings are directly relevant to claims by women who lived near EtO facilities
FAQ

Frequently Asked Questions

See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
Related Topics

Related Pages

Lymphoma from EtO Exposure

Non-Hodgkin lymphoma is the most strongly linked cancer to ethylene oxide exposure, with studies showing elevated rates of lymphoid cancers in both facility workers and nearby community members.

lymphomanon-hodgkin-lymphomablood-cancer
Learn more

Trump ETO Regulatory Rollback

On July 17, 2025, President Trump issued a proclamation invoking Clean Air Act §112(i)(4) to grant 41 ethylene oxide sterilization facilities a 2-year delay in complying with the EPA's 2024 NESHAP emission standards. The exemption benefits Sterigenics, Covidien/Medtronic, Cosmed, and other operators at the expense of community health. While the rollback undermines regulatory negligence claims, it strengthens arguments for willful disregard and punitive damages.

trumpregulatory-rollbackneshap
Learn more

Breast Cancer & Ethylene Oxide

Breast cancer linked to EtO exposure was at the center of the landmark $363 million Sterigenics verdict in Georgia — the first major EtO trial to produce a jury verdict.

breast-cancersterigenicsgeorgia
Learn more

Sterigenics Lawsuits

Sterigenics International, now a subsidiary of Sotera Health, faces hundreds of lawsuits in Georgia and Illinois from community members who developed cancer after living near its facilities.

sterigenicssotera-healthwillowbrook
Learn more

Facility Worker Exposure Claims

Workers inside EtO sterilization and chemical manufacturing facilities face the highest exposure levels — often hundreds of times greater than community ambient levels — and have the strongest causation cases.

occupational-exposureworkersosha
Learn more
Parent Case

Ethylene Oxide Lawsuit

Ethylene oxide (EtO) is a highly toxic chemical used to sterilize medical equipment and manufacture other chemicals. The EPA determined in 2016 that EtO is carcinogenic to humans at exposure levels far lower than previously thought. Residents living near EtO-emitting facilities in Georgia, Illinois, Texas, Colorado, and other states have filed lawsuits alleging their cancers — including lymphoma, breast cancer, and leukemia — were caused by chronic exposure to EtO emissions.

View full case overview